Candida parapsilosis in Bronchial Wash: Treatment Approach
Candida parapsilosis isolated from bronchoalveolar lavage (bronchial wash) in immunocompetent patients typically represents colonization and does not require antifungal treatment. 1
Key Guideline Recommendation
The 2016 IDSA guidelines explicitly state: "Growth of Candida from respiratory secretions usually indicates colonization and rarely requires treatment with antifungal therapy" 1. This is a strong recommendation based on moderate-quality evidence and applies directly to your clinical scenario.
Supporting Evidence
A retrospective study of 62 critically ill trauma patients with Candida species isolated from BAL cultures found that:
- 92% of episodes were considered contaminants and not treated with antifungals
- No colony counts exceeded the diagnostic threshold for bacterial VAP (≥10⁵ cfu/ml)
- No patients developed subsequent candidemia
- 74% of follow-up BAL cultures were negative for Candida
- Overall mortality (17%) was similar to matched controls without Candida isolation 2
This strongly supports that Candida in bronchial wash specimens below diagnostic thresholds does not require treatment.
When to Consider Treatment
Antifungal therapy should only be considered if:
- Invasive disease is documented elsewhere (e.g., candidemia, disseminated candidiasis)
- High colony counts are present (≥10⁵ cfu/ml, though this threshold is not well-established for fungal VAP)
- Severe immunosuppression exists (neutropenia, solid organ transplant, high-dose corticosteroids)
- Clinical deterioration despite appropriate antibacterial therapy with no other explanation
- Histopathologic evidence of tissue invasion on lung biopsy
If Treatment Is Warranted
Should you determine that true invasive pulmonary candidiasis exists (rare), treatment follows candidemia guidelines:
First-line therapy:
- Echinocandin (caspofungin 70 mg loading, then 50 mg daily; micafungin 100 mg daily; anidulafungin 200 mg loading, then 100 mg daily) 1
Alternative for non-critically ill patients:
- Fluconazole 800 mg loading, then 400 mg daily (C. parapsilosis is typically fluconazole-susceptible) 1
Important Note on C. parapsilosis and Echinocandins
Previous guidelines favored fluconazole over echinocandins for C. parapsilosis due to decreased in vitro echinocandin activity. However, recent evidence shows no clinical difference in outcomes between echinocandins and fluconazole for C. parapsilosis infections 1, 3. A 2016 retrospective study of 307 patients with C. parapsilosis candidemia found no difference in 30-day mortality between echinocandin and fluconazole treatment (OR 0.82,95% CI 0.33-2.07) 3.
Critical Pitfalls to Avoid
Do not treat colonization: The vast majority of Candida in respiratory specimens represents colonization, not infection. Unnecessary antifungal therapy exposes patients to drug toxicity, cost, and potential resistance development.
Do not rely on β-D-glucan from BAL: Limited data show poor positive predictive values for β-D-glucan in bronchoalveolar lavage fluid for diagnosing fungal pneumonia 1.
Obtain susceptibility testing: If treatment is initiated, test for azole susceptibility on all clinically relevant isolates. Consider echinocandin susceptibility testing for C. parapsilosis given the species-specific concerns 1.
Bottom Line
In the absence of documented invasive disease, severe immunosuppression, or tissue invasion, observe the patient without antifungal therapy. The isolation of C. parapsilosis from bronchial wash is almost certainly colonization and treating it may cause more harm than benefit.